The fight over drug patents in India is quickly ratcheting up even as other countries are looking at new twists on the model for getting their hands on cheaper drugs.
Teva Pharmaceutical Industries is looking to cut $2 billion in annual costs over the next few years, much of that from its extensive manufacturing network. While the Israeli company is evaluating each plant in its extensive global network, analysts suggest it will be hard for Teva not to cut on the home turf, even in the face of political blowback.
Saladax Biomedical drew a $22.4 million cash infusion from a major Chinese pharmaceutical company that will help advance development and expanded sales efforts for its cancer treatment dose management diagnostic tests.
If AstraZeneca decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb. The Wall Street Journal reports that Bristol-Myers has been kicking tires around the industry, most recently at Biogen Idec.
The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds.
The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds. The drugs, sold by Merck and a Bristol-Myers Squibb/AstraZeneca partnership, have been linked to pancreatitis before, but the JAMA Internal Medicine study puts a number to that risk for the first time.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
The well-armed German pricing gatekeepers have dismissed two more Big Pharma drugs. Pfizer's ($PFE) lung cancer treatment Xalkori and the Bristol-Myers Squibb ($BMY)/AstraZeneca ($AZN) diabetes drug Komboglyze both got an initial thumbs-down from the Institute for Quality and Efficiency in Health Care (IQWiG).
From a strictly numbers point of view, last year's results are pretty obvious. As the accompanying chart indicates, 2012 was the slowest in 5 years in terms of both number of deals and dollars on the table. To Christian Dokomajilar, manager and senior biotech analyst at Deloitte Recap, that actually bodes well for 2013. Read the report >>
A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version.